CLINICAL_TRIALS
trial_result
· 2022-10-24
Clinical Trial Update: MSB11456 in Participants With Moderately to Severely Active Rheumatoid Arthritis [Phase 3]
Summary
Phase 3 trial update for MSB11456 in moderately to severely active rheumatoid arthritis; study completed with posted results.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Fresenius Kabi SwissBioSim GmbH | Conditions: Rheumatoid Arthritis | Phase 3 | Status: COMPLETED | Results posted: 2022-10-24